What are the indications, dosing guidelines, contraindications, monitoring requirements, and common side effects of atomoxetine for treating ADHD?

Atomoxetine for ADHD

Indication

Atomoxetine is a selective norepinephrine reuptake inhibitor FDA-approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults. 1 It represents the first nonstimulant medication approved for ADHD and is not classified as a controlled substance. 1

Dosing Guidelines

Initial and Target Dosing

For children and adolescents weighing ≤70 kg:

• Initial dose: 0.5 mg/kg/day 1
• Target dose: 1.2 mg/kg/day 1
• Maximum dose: 1.4 mg/kg/day 1

For children and adolescents >70 kg and adults:

• Initial dose: 40 mg/day 1
• Target dose: 80 mg/day 1
• Maximum dose: 100 mg/day 1

Dosing Schedule and Titration

Atomoxetine can be administered as either a single daily dose or divided into two evenly split doses. 2 A critical clinical pitfall is underdosing—real-world data show adults frequently receive only 60 mg/day rather than the recommended 80 mg/day target. 3 Patients must remain at target dose for 4-6 weeks before judging efficacy. 3

Dose Adjustments

Dose reductions are required for:

• Hepatic impairment 1
• Concomitant use of strong CYP2D6 inhibitors (e.g., paroxetine) 1
• Known CYP2D6 poor metabolizers 1

Poor CYP2D6 metabolizers experience greater drug exposure and slower elimination, necessitating lower doses. 2

Contraindications

Absolute contraindications include: 1

• Hypersensitivity to atomoxetine or product constituents
• Use within 2 weeks of MAOI discontinuation or other drugs affecting brain monoamine concentrations
• Narrow-angle glaucoma
• Pheochromocytoma or history of pheochromocytoma
• Severe cardiovascular disorders that might deteriorate with clinically important increases in heart rate and blood pressure

Relative contraindications and cautions: 1

• Known serious structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm abnormalities in children/adolescents (generally should not be used)
• Clinically significant cardiac abnormalities in adults (consideration should be given to not using)

Monitoring Requirements

Cardiovascular Monitoring

Before initiating atomoxetine, obtain: 4

• Personal history of cardiac symptoms
• Family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome
• If risk factors present: obtain ECG and possibly refer to pediatric cardiologist if ECG abnormal 4

During treatment, monitor: 4

• Blood pressure and heart rate (atomoxetine increases both parameters) 4
• Patients should undergo prompt cardiac evaluation if emergent cardiovascular symptoms develop 1

Psychiatric and Behavioral Monitoring

Monitor closely for: 1

• Suicidal ideation, clinical worsening, and unusual behavioral changes (FDA black box warning for increased risk in children/adolescents) 1
• Emergence of psychotic or manic symptoms (consider discontinuation if these occur) 1
• Appearance or worsening of aggressive behavior or hostility 1

Screen for bipolar disorder before initiating treatment. 1

Growth Monitoring

Monitor height and weight in pediatric patients. 1 Atomoxetine causes initial growth delays in the first 1-2 years of treatment, with return to expected measurements after 2-3 years on average. 4

Hepatic Monitoring

Discontinue atomoxetine and do not restart if jaundice or laboratory evidence of liver injury develops. 1 Severe liver injury, though extremely rare, has been reported. 2

Additional Monitoring

• Urinary symptoms (hesitancy and retention may occur) 1
• Priapism (requires prompt medical attention if suspected) 1

Common Side Effects

Children and Adolescents

Most common adverse reactions (≥5% and at least twice placebo incidence): 1

• Nausea
• Vomiting
• Fatigue
• Decreased appetite
• Abdominal pain
• Somnolence

Adults

Most common adverse reactions: 1

• Constipation
• Dry mouth
• Nausea
• Fatigue
• Decreased appetite
• Dizziness
• Erectile dysfunction
• Urinary hesitation

Tolerability Profile

The majority of adverse events are mild to moderate in severity. 2 Discontinuation rates due to adverse events are low (3.5% vs 1.4% for placebo), though rates increase at doses >1.5 mg/kg/day. 5 Adverse events tend to appear early in treatment and then decline. 6

Compared to stimulants, atomoxetine causes more somnolence but less insomnia. 2 Extensive CYP2D6 metabolizers tolerate atomoxetine better than poor metabolizers. 2

Clinical Positioning

Atomoxetine is particularly useful for patients: 2

• At risk of substance abuse (no abuse potential, not a controlled substance)
• With comorbid anxiety or tics
• Who do not wish to take a controlled substance
• Who cannot tolerate stimulants or have contraindications to stimulant use

According to the 2019 AAP guidelines, stimulants remain first-line pharmacological treatment for ADHD. 4 However, atomoxetine provides an important alternative when stimulants are inappropriate or ineffective. 4

Atomoxetine can be used as adjunctive therapy with stimulants when stimulant monotherapy is not fully effective or limited by side effects, though this is off-label. 4